* The following is a press release on Investor Relations (IR) presentation held by Cheil Industries on June 30.

The shareholders of Samsung C&T may refer to the following material to learn more about the vision for the

merged entity and growth strategies by business and initiatives for shareholder value enhancement.

On June 30, Cheil Industries held an IR meeting with research analysts in Yeouido, Seoul, to share its corporate vision, potential synergies and growth strategies by business division, and various initiatives the Company is considering to enhance shareholder value post the merger.

Cheil Industries' co-CEOs, Joo Hwa Yoon and Bong Young Kim, along with Samsung C&T's CEO, Shin Kim and other key members of the senior management team from both companies were in attendance.

Cheil Industries CEO Joo Hwa Yoon noted that "Based on various opinions and feedback received during prior IR events held in Korea and abroad, we have arranged today's discussion forum to explain in detail the combined entity's corporate vision and its strong commitment to shareholder value enhancement".

Building on its corporate vision to become the "Global Business Partner & Lifestyle Innovator," the combined entity aims to achieve KRW 60 trillion in revenue and KRW 4 trillion in pre-tax income by 2020 by maintaining stable growth in the B2B construction and trading businesses, becoming a global leader in food services and leisure, and capitalizing on new growth opportunities such as the bio business.

The management team expressed confidence in the merged entity's ability to deliver strong growth by combining Cheil Industries and Samsung C&T's respective expertise, and as the de facto holding company of Samsung group, to lead new business initiatives and capitalize on future growth opportunities in healthcare, energy, and other sectors.

Cheol Bo Yang, Vice President of Samsung Bioepis who was also in attendance, said "We are considering various alternatives for our bio business, including a potential listing on the Nasdaq market to fund our R&D expenditures. We expect the valuation of our bio business to reflect the valuation level of those peers that are already listed on the Nasdaq market and domestic peers such as Celltrion."

In addition, the Company announced various initiatives for shareholder value enhancement including increasing the dividend payout ratio and establishing a separate governance committee. It also expressed its commitment to maintaining active dialogue with shareholders going forward and setting up an organization dedicated to leading CSR activities.

Taking into consideration its business performance and investment needs for future growth, the merged entity will seek to gradually increase its dividend payout ratio to 30%.

Furthermore, to strengthen the BoD's independence, a governance committee consisting entirely of independent directors will be newly established. The committee will be responsible for reviewing business decisions that can directly impact shareholder value such as related-party transactions and material divestitures and acquisitions. One of the committee members will be designated as the director in charge of ensuring that the shareholders are well represented and will act as a key communication channel between the BoD and the shareholders.

The merged entity will seek to implement various shareholder value enhancement measures including dividend payouts and share buybacks adopted by globally recognized market leaders. The Company will also establish a clear communication plan to reach out to various stakeholders including minority shareholders to proactively gather and reflect market feedback.

The combined entity will also set up an organization dedicated to leading CSR activities comprised of external experts and relevant members from within the Company. The Company plans to work with the new CSR organization to study precedents of social contributions made by market-leading global companies and reflect those findings in its corporate policy.

distributed by